Understanding the role of NRF2-regulated miRNAs in human malignancies

Niraj M Shah; Stuart A Rushworth; Megan Y Murray; Kristian M Bowles; David J MacEwan

doi:10.18632/oncotarget.1181

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Understanding the role of NRF2-regulated miRNAs in human malignancies

Niraj M Shah, Stuart A Rushworth, Megan Y Murray, Kristian M Bowles and David J MacEwan _

PDF | HTML | How to cite

Oncotarget. 2013; 4:1130-1142. https://doi.org/10.18632/oncotarget.1181

Metrics: PDF 3890 views | HTML 3603 views | ?

Abstract

Niraj M Shah1,2, Stuart A Rushworth1, Megan Y Murray1, Kristian M Bowles1 and David J MacEwan2

1 Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom

2 MRC Centre for Drug Safety Science, Department of Clinical and Molecular Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

Correspondence:

David J MacEwan, email:

Keywords: NRF2, miRNA, transcription factor, oncogenesis, drug resistance

Received: July 15, 2013 Accepted: August 6, 2013 Published: August 8, 2013

Abstract

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a key transcription factor that regulates the expression of over a hundred cytoprotective and antioxidant genes that provide cellular protection from reactive oxygen species. Chemotherapy resistance in several cancers has been linked to dysregulation of the NRF2 signalling pathway, moreover there is growing evidence that NRF2 may contribute to tumorigenesis. MicroRNA (miRNA) are small non-coding RNA sequences that post-transcriptionally regulate mRNA sequences. In cancer pathogenesis, aberrantly expressed miRNAs can act as either tumor suppressor or oncogenic miRNA. Recent evidence has been described that identifies a number of miRNA that can be regulated by NRF2. This review outlines the importance of NRF2 in regulating miRNA, and the functional role this may have in the tumorigenesis of human malignancies and their chemotherapy resistance.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1181

Publication Alerts

Reviews:

Understanding the role of NRF2-regulated miRNAs in human malignancies

Abstract